OPT Share Price Performance
AU$0
-0.02 (-100.00%)
Price AU$0
Fair ValueAU$0.10
Share Pricen/a
Opthea Limited Stock Price
- 2 Narratives written by author
- 2 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
OPT Community Narratives
ST
Fair Value
·Fair Value AU$0.1 87.0% undervalued intrinsic discount
OPTHEA - Write-off
17users have liked this narrative
2users have commented on this narrative
27users have followed this narrative
BA
Fair Value
·Fair Value AU$0.61 97.9% undervalued intrinsic discount
Opthea Test
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Opthea Test
Opthea is testing a new add-on treatment for a common cause of vision loss that aims to help patients keep their sight for longer when used with today’s standard drugs. With late-stage trial results coming soon and big drugmakers already active in this area, the next year could decide whether this becomes a widely used new option—or a costly setback.Read more
OPTHEA - Write-off
--- [Narrative update per Investor announcement 24-Mar-2025] --- The analysis below was written ahead of Opthea’s Phase 3 results. As stated, the thesis was highly dependent on trial success.Read more
ST
AU$0.1
87.0% undervalued intrinsic discount
Fair Value
Profit Margin
100%
Future PE
500x
Price in 2034
AU$0.15
Trending Discussion
Recently Updated Narratives
ST
OPTHEA - Write-off
Fair Value: AU$0.1 87.0% undervalued intrinsic discount
27 fair values setusers have set this as their fair value
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
BA
Opthea Test
Fair Value: AU$0.61 97.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Opthea Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 0.22
- 100.00%
- -1,476,212.82%
- 0%
About OPT
- Founded
- 1984
- Employees
- 33
- CEO
- WebsiteView website
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
